To evaluate the efficacy of CT-based radiomics in differentiating benign from malignant renal tumors, predicting nuclear grading of renal cell carcinoma, and assessing T-stage of renal tumors, thereby exploring its clinical application value.
Study Type
OBSERVATIONAL
Enrollment
700
Second Xiangya Hospital
Changsha, Hunan, China
CT-based radiomics analysis for benign and malignant tumor differentiation
Histopathological diagnosis served as the gold standard, with tumors classified into: (1) Benign renal tumors: Including lipid-poor angiomyolipoma and renal oncocytoma; (2) Malignant renal tumors: Comprising clear cell renal cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma
Time frame: within 1 month
CT-based radiomics analysis for nuclear grading of clear cell renal cell carcinoma (ccRCC)
Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low grade ccRCC: Including WHO/ISUP grade 1-2 ccRCC; (2) high grade ccRCC: Including WHO/ISUP grade 3-4 ccRCC
Time frame: within 1 month
CT-based radiomics analysis of T-stage classification of renal cell carcinoma (RCC)
Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low T-stage RCC: Including T1-2 RCC; (2) high T-stage RCC: including T3-4 RCC
Time frame: within 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.